GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

prifetrastat   Click here for help

GtoPdb Ligand ID: 14088

Synonyms: example 34 [WO2020254946] | PF-07248144 | PF07248144
Compound class: Synthetic organic
Comment: Prifetrastat (PF-07248144) is a histone lysine acetyltransferase KAT6A/B inhibitor [2,4]. Inhibition of histone acetyltransferases KAT6A/B induces senescence and arrests tumour growth [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 110.2
Molecular weight 414.44
XLogP 1.62
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC1=C(C=CC=C1)S(=O)(=O)NC2=NOC3=C2C(=CC(=C3)CN4C=CC=N4)OC
Isomeric SMILES COC1=CC=CC=C1S(=O)(=O)NC2=NOC3=C2C(=CC(=C3)CN4C=CC=N4)OC
InChI InChI=1S/C19H18N4O5S/c1-26-14-6-3-4-7-17(14)29(24,25)22-19-18-15(27-2)10-13(11-16(18)28-21-19)12-23-9-5-8-20-23/h3-11H,12H2,1-2H3,(H,21,22)
InChI Key RCBWSTJGOASLEO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, Nguyen N, Wichmann J, McRae HM, Yang Y et al.. (2018)
Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Nature, 560 (7717): 253-257. [PMID:30069049]
2. Bozikis YEB, Brodsky O, Camerino MA, Greasley SE, Hoffman RL, Kumpf RA, Kung PP, Richardson PF, Stupple PA, Sutton SC. (2020)
Benzisoxazole sulfonamide derivatives.
Patent number: WO2020254946A1. Assignee: Pfizer Inc., Ctxt Pty Ltd. Priority date: 16/06/2020. Publication date: 24/12/2020.
3. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM et al.. (2024)
Author Correction: Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Nat Med, 30 (8): 2371. [PMID:38914862]
4. Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM et al.. (2024)
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Nat Med, 30 (8): 2242-2250. [PMID:38824244]